Clinical Trial Update: MK-3475 Immunotherapy in Endometrial Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pembrolizumab (MK-3475) in endometrial cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Endometrial Cancer, Endometrial Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2025-01-03